Page 1

1/29/26 , 5:28 PM Document EX - 99.1 2 a20210930ex991 earningsrele.htm EX - 99.1 endo Exhibit 99.1 ENDO REPORTS THIRD - QUARTER 2021 FINANCIAL RESULTS AND RAISES 2021 FINANCIAL GUIDANCE DUBLIN , November 4 , 2021 -- - Endo International plc ( NASDAQ : ENDP ) today reported financial results for the third - quarter ended September 30 , 2021 . " We delivered strong third - quarter results driven by outstanding execution across all of our businesses . As a result of our year - to - date performance and our expectations for the remainder of 2021 , we are raising our full - year 2021 financial guidance , " said Blaise Coleman , President and Chief Executive Officer at Endo . " Additionally , we are pleased with our progress against our strategic priorities including our efforts to expand and enhance our portfolio with the recent launch of varenicline tablets , the only available FDA approved generic version of Chantix® , and the continued positive market response to QWO® . " THIRD - QUARTER FINANCIAL PERFORMANCE ( in thousands , except per share amounts ) Three Months Ended September 30 , 2021 2020 Total Revenues , Net $ 772,028 $ 634,860 Change 22 % $ Nine Months Ended September 30 , 2021 2020 Change 2,203,777 $ 2,142,853 3 % Reported ( Loss ) Income from Continuing Operations $ ( 49,289 ) $ ( 68,974 ) ( 29 ) % $ Reported Diluted Weighted Average Shares 233,578 230,040 2 % ( 12,414 ) $ 232,487 106,217 NM 233,379 % Reported Diluted Net ( Loss ) Income per Share from Continuing Operations $ ( 0.21 ) $ ( 0.30 ) Reported Net ( Loss ) Income $ ( 77,207 ) $ ( 75,887 ) Adjusted Income from Continuing Operations ( 2 ) $ 189,277 $ 122,275 ( 30 ) % $ 2 % $ 55 % $ ( 0.05 ) $ 0.46 NM ( 51,183 ) $ 64,601 NM 516,315 $ 494,375 4 % Adjusted Diluted Weighted Average Shares ( 1 ) ( 2 ) 235,527 233,442 1 % 236,538 233,379 1 % Adjusted Diluted Net Income per Share from Continuing Operations ( 2 ) $ Adjusted EBITDA ( 2 ) $ 0.80 $ 386,883 $ 0.52 286,700 54 % $ 35 % $ 2.18 $ 2.12 3 % 1,094,298 $ 1,044,307 5 % ( 1 ) Reported Diluted Net ( Loss ) Income per Share from Continuing Operations is computed based on weighted average shares outstanding and , if there is income from continuing operations during the period , the dilutive impact of ordinary share equivalents outstanding during the period . In the case of Adjusted Diluted Weighted Average Shares , Adjusted Income from Continuing Operations is used in determining whether to include such dilutive impact . ( 2 ) The information presented in the table above includes non - GAAP financial measures such as " Adjusted Income from Continuing Operations , " " Adjusted Diluted Weighted Average Shares , " " Adjusted Diluted Net Income per Share from Continuing Operations " and " Adjusted EBITDA . " Refer to the " Supplemental Financial Information " section below for reconciliations of certain non- GAAP financial measures to the most directly comparable GAAP financial measures . CONSOLIDATED RESULTS Total revenues were $ 772 million in third - quarter 2021 , an increase of 22 % compared to $ 635 million during the same period in 2020 . This result was primarily attributable to increased revenues from our Sterile Injectables , Generic Pharmaceuticals , and Branded Pharmaceuticals segments . 1 https://www.sec.gov/Archives/edgar/data/1593034/000159303421000097/a20210930ex991 earningsrele.htm 1/21